Mosconi Paola, Colombo Cinzia, Satolli Roberto, Carzaniga Sara
Laboratory for medical research and consumer involvement, IRCCS Istituto di Ricerche Farmacologiche Mario Negri, Milano, Italy.
Agenzia di Editoria Scientifica Zadig, Milano, Italy.
PLoS One. 2016 Jan 11;11(1):e0143176. doi: 10.1371/journal.pone.0143176. eCollection 2016.
Most public health agencies and learned societies agree that the prostate-specific antigen (PSA) test in asymptomatic men should not be recommended, on account of its potential for harm. Yet PSA is still widely used as a screening test and is not being abandoned. This remains a significant public health issue, and citizens' engagement is needed. This study was designed to produce a deliberation on the PSA screening test by a citizens' jury.
Fifteen citizens were selected and balanced for sex, age, and education. They received an information booklet and participated in a two-day meeting with experts to reach a deliberation on the question "Should the National Health Service discourage or recommend PSA as an individual screening test for prostate cancer in men 55-69 years old?". A facilitator ran the jurors' discussion.
All except three of the jurors decided that the National Health Service should discourage the use of PSA as an individual screening test for prostate cancer in 55-69 year-old men. The jury was particularly convinced by the uncertainty of the test outcomes, the utility of the test, and its cost/benefit ratio. Before the meeting 60% of jurors would have recommended the test to a relative, and all the male jurors would have done so. After the meeting these percentages fell to 15% and 12%.
This experience confirms the feasibility and effectiveness of delegating to a group of citizens the responsibility to decide on public health issues on behalf of the community. Public health authorities should invest in information campaigns aimed at the public and in educational initiatives for physicians. This also provided an opportunity to disseminate information on screening, over-diagnosis, and over-treatment.
大多数公共卫生机构和学术团体都认为,由于存在潜在危害,不应建议无症状男性进行前列腺特异性抗原(PSA)检测。然而,PSA仍被广泛用作筛查测试,并未被摒弃。这仍是一个重大的公共卫生问题,需要公民的参与。本研究旨在通过公民陪审团对PSA筛查测试进行审议。
挑选了15名公民,并在性别、年龄和教育程度方面进行了平衡。他们收到了一本信息手册,并参加了与专家为期两天的会议,以就“国家医疗服务体系应劝阻还是推荐PSA作为55 - 69岁男性前列腺癌的个体筛查测试?”这一问题达成审议结果。一名主持人主持陪审员的讨论。
除三名陪审员外,所有陪审员都决定国家医疗服务体系应劝阻在55 - 69岁男性中使用PSA作为前列腺癌的个体筛查测试。陪审团尤其被测试结果的不确定性、测试的效用及其成本效益比所说服。会议前,60%的陪审员会向亲属推荐该测试,所有男性陪审员都会这样做。会议后,这些比例降至15%和12%。
这一经验证实了委托一组公民代表社区决定公共卫生问题的可行性和有效性。公共卫生当局应投资针对公众的宣传活动以及针对医生的教育倡议。这也提供了一个传播有关筛查、过度诊断和过度治疗信息的机会。